Anti-angiogenesis and angioprevention: Mechanisms, problems and perspectives

Cancer Detection and Prevention

Volumn 27, Issue 3, 2003, Pages 229-238

  Bisacchi, D ^a   Benelli, R ^a   Vanzetto, C ^b   Ferrari, N ^a   Tosetti, F ^a   Albini, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Angioprevention; Anti angiogenesis; Chemoprevention; Endothelial cell; Metastasis; Tumor progression

Indexed keywords

EID: 0038687221     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(03)00030-8     Document Type: Article

References (122)

1. Folkman J. Tumor angiogenesis: therapeutic implications. New England J Med 1971;285:1182-6.
2. Gimbrone MAJ, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136(2):261-76.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64.
4. Jones N, Iljin K, Dumont DJ, Alitalo K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001;2(4):257-67.
5. Connolly D, Heuvelman D, Nelson R, Olander J, Eppley B, Delfino J, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;54(5):1470-8.
6. Plate K, Breier G, Weich H, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359(6389):845-8.
7. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Path 1996;149(6):1851-69.
8. Yoshiji H, Gomez D, Shibuya M, Thorgeirsson U. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996;56(9):2013-6.
9. Aoki Y, Tosato G. Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leuk Lymphoma 2001;41(3-4):229-37.
10. Plate K, Breier G, Weich H, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359(6398):845-8.
11. Phillips G, Stone A, Jones B, Schultz J, Whitehead R, Knighton D. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1994;8(6):961-5.
12. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi C, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving thc alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996;149(1):293-305.
13. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13(1):9-22.
14. Cross M, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22(4):201-7.
15. Benjamin L, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94(16):8761-6.
16. Stacker S, Vitali A, Caesar C, Domagala T, Groenen L, Nice E, et al. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem 1999;274(49):34884-92.
17. Masood R, Cai J, Zheng T, Smith D, Hinton D, Gill P. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98(6):1904-13.
18. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843-5.
19. Wenger R. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 2000;203(8):1253-63.
20. Nagase H, Woessner JJ. Matrix metalloproteinases. J Biol Chem 1999;274(31):21491-4.
21. Westermarck J, Kahari V. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13(8):781-92.
22. Shapiro S. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10(5):602-8.
23. Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995;14(5):908-17.
24. Sternlicht M, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
25. Meade-Tollin L, Way D, Witte M. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem 1999;101(3):305-16.
26. Davidson B, Goldberg I, Gotlieb W, Kopolovic J, Ben-Baruch G, Nesland J, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17(10):799-808.
27. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58(5):1048-51.
28. Vu T, Shipley J, Bergers G, Berger J, Helms J, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93(3):411-22.
29. Rabbani S, Xing R. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 1998;12(4):911-20.
30. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357(9255):539-45.
31. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97(2):339-45.
32. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002;19(3):247-58.
33. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7.
34. Parkin D, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49(1):33-64.
35. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
36. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA. The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195-203.
37. Addison C, Daniel T, Burdick M, Liu H, Ehlert J, Xue Y, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J Immunol 2000;165(9):5269-77.
38. Sgadari C, Angiolillo A, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87(9):3877-82.
39. Koch A, Polverini P, Kunkel S, Harlow L, DiPietro L, Elner V, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258(5089):1798-801.
40. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002;16(2):267-9.
41. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, et al. The angiogenesis induced by HIV-1 Tat is mediated by the flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2(12):1371-5.
42. Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 1998;95(22):13153-8.
43. Albini A, Benelli R, Presta M, Rusnati M, Ziche M, Rubartelli A, et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996;12:289-97.
44. Vene R, Benelli R, Noonan D, Albini A. HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis. Clin Exp Metastasis 2000;18(7):533-8.
45. O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277-85.
46. O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79(2):315-28.
47. O'Reilly M, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2(6):689-92.
48. Griscelli F, Li H, Bennaceur GA, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998;95(11):6367-72.
49. Feldman A, Alexander H, Hewitt S, Lorang D, Thiruvathukal C, Turner E, et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst 2001;93(13):1014-20.
50. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161(12):6845-52.
51. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272(46):28823-5.
52. Wen W, Moses M, Wiederschain D, Arbiser J, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999;59(24):6052-6.
53. Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002;168(11):5798-804.
54. Strik H, Schluesener H, Seid K, Meyermann R, Deininger M. Localization of endostatin in rat and human gliomas. Cancer 2001;91(5):1013-9.
55. Hanai JJ, Dhanabal M, Karumanchi S, Albanese C, Waterman M, Chan B, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1, J Biol Chem 2002;277(19):16464-9.
56. Cao Y, Chen A, An S, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997;272(36):22924-8.
57. Ji W, Castellino F, Chang Y, Deford M, Gray H, Villarreal X, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998;12(15):1731-8.
58. Claesson WL, Welsh M, Ito N, Anand AB, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998;95(10):5579-83.
59. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J 2001;15(6):1044-53.
60. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999;96(6):2811-6.
61. Jiang L, Jha V, Dhanabal M, Sukhatme V, Alper S. Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. Am J Physiol Cell Physiol 2001;280(5):C1140-50.
62. Cao Y, Veitonmaki N, Keough K, Cheng H, Lee L, Zurakowski D. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int J Mol Med 2000;5(5):547-51.
63. Feldman A, Tamarkin L, Paciotti G, Simpson B, Linehan W, Yang J, et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000;6(12):4628-34.
64. Mannello F, Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001;6(6):479-82.
65. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001;158(4):1207-15.
66. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15(1):61-75.
67. Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2002;2(2):255-71.
68. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91(4):1198-205.
69. Gohji K, Fidler IJ, Tsan R, Radinsky R, Von Eschenbach AC, Tsuruo T, et al. Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 1994;58(3):380-4.
70. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 2000;156(4):1381-93.
71. Giavazzi R, Giuliani R, Coltrini D, Bani M, Ferri C, Sennino B, et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res 2001;61(1):309-17.
72. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16(1):2-14.
73. Albini A, D'Agostini F, Giunciuglio D, Paglieri I, Balansky RM, De Flora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer 1995;61:121-9.
74. Cai T, Fassina G, Morini M, Aluigi M, Masiello L, Fontanini G, et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest 1999;79(9):1151-9.
75. Albini A, Morini M, D'Agostini F, Ferrari N, Campelli F, Arena G, et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 2001;61(22):8171-8.
76. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000;130(Suppl 2S):467S-71S.
77. Griffiths K, Morton MS, Denis L. Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Eur Urol 1999;35(5-6):443-55.
78. Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 2001;84(6):844-50.
79. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 1998;58(21):4851-7.
80. Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R, Albini A. Tumor invasion: molecular shears blunted by green tea. Nat Med 1999;5(11):1216.
81. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 2001;91(4):822-32.
82. Dell'Aica I, Dona M, Sartor L, Pezzato E, Garbisa S. (-)Epigallocatechin-3-gallate directly inhibits MT1-MMP activity, leading to accumulation of non-activated MMP-2 at the cell surface. Lab Invest 2002;82(12):1685-93.
83. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999;398(6726):381.
84. Sartor L, Pezzato E, Garbisa S. (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion. J Leukoc Biol 2002;71(1):73-9.
85. Donà M, Dell'Aica I, Calabrese F, Benelli R, Morini M, Albini A, et al. Neutrophil restraint by green tea: inhibition of inflammation and associated angiogenesis and pulmonary fibrosis. J Immunol 2003 [in press].
86. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular eudothelial growth factor receptor phosphorylation. Cancer Res 2002;62(2):381-5.
87. Jankun J, Selman SH, Swiercz R, Skrzypczak JE. Why drinking green tea could prevent cancer. Nature 1997;387(6633):561.
88. Katiyar SK, Challa A, McCormick TS, Cooper KD, Mukhtar H. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol(-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis 1999;20(11):2117-24.
89. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58(3):409-12.
90. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164(3 Pt 1):820-5.
91. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs; insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5(12):1418-23.
92. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60(5):1306-11.
93. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2(COX-2). Cell 1996;87(5):803-9.
94. De Flora S, Izzotti A, D'Agostini F, Balansky RM. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 2001;22(7):999-1013.
95. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21(3):525-30.
96. Lingen MW, Polverini PJ, Bouck NP. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 1996;74(2):476-83.
97. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol 1996;149(1):247-58.
98. Iurlaro M, Benelli R, Masiello L, Rosso M, Santi L, Albini A. Beta interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid. Eur J Cancer 1998;34(4):570-6.
99. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer 1994;57(1):81-5.
100. Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000;275(1):642-50.
101. Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C, Chambon P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J 1990;9(13):4443-54.
102. Schroen DJ, Brinckerhoff CE. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Exp 1996;6(4):197-207.
103. Braunhut SJ, Moses MA. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem 1994;269(18):13472-9.
104. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997;57(14):2890-5.
105. Bengtson EM, Rigas JR. New oral chemotherapeutic agents for lung cancer. Drugs 1999;58(Suppl 3):57-69.
106. Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 2001;94(3):314-21.
107. Park BH, Breyer B, He TC. Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer. Curr Opin Oncol 2001;13(1):78-83.
108. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274(13):9116-21.
109. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy delta 12,14-prostaglandin J2. J Biol Chem 1999;274(24):17042-8.
110. Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, et al. Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines. Endocrinology 2000;141(7):2567-73.
111. Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001;276(12):9101-7.
112. 3 inhibits angiogenesis in vitro and in vivo. Cir Res 2000;87(3):214-20.
113. 3 receptor agonist. Blood 2000;96(9):3188-94.
114. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994;269(6):4355-9.
115. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, et al. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol 1999;19(10):6742-53.
116. Buttice G, Quinones S, Kurkinen M. The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene. Nucl Acids Res 1991;19(13):3723-31.
117. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997;272(15):9962-70.
118. Bergelson S, Pinkus R, Daniel V. Intracellular glutathione levels regulate fos/jun induction and activation of glutathione S-transferase gene expression. Cancer Res 1994;54:36-40.
119. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, et al. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci USA 1991;88(14):6092-6.
120. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M, et al. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271(37):22441-6.
121. Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, et al. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann New York Acad Sci 2000;902:187-200.
122. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18(13):2221-30.